TG100-115 | CAS#677297-51-7 | PI3K γ inhibitor

MedKoo Cat#: 202892 | Name: TG100-115

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TG100-115, inhibited PI3K γ and -δ(IC50 values of 83 and 235 nM, respectively), whereas both PI3Kα and -β were relatively unaffected (IC50 values>1 μM). As a gauge of general specificity, TG100-115 was also assayed against a 133 protein kinase panel, none of which was inhibited at IC50 values <1 μM.

Chemical Structure

TG100-115

CAS#677297-51-7

Theoretical Analysis

MedKoo Cat#: 202892

Name: TG100-115

CAS#: 677297-51-7

Chemical Formula: C18H14N6O2

Exact Mass: 346.1178

Molecular Weight: 346.34

Elemental Analysis: C, 62.42; H, 4.07; N, 24.27; O, 9.24

Price and Availability

Size	Price	Availability
25mg	USD 250.00
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,350.00	2 Weeks
500mg	USD 2,850.00	2 Weeks
1g	USD 3,950.00	2 Weeks
2g	USD 6,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

TG100115; TG-100115; TG 100115; TG-100-115; TG100-115 ; TG 100-115.

IUPAC/Chemical Name

3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol

InChi Key

UJIAQDJKSXQLIT-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H14N6O2/c19-16-15-17(24-18(20)23-16)22-14(10-4-2-6-12(26)8-10)13(21-15)9-3-1-5-11(25)7-9/h1-8,25-26H,(H4,19,20,22,23,24)

SMILES Code

OC1=CC=CC(C2=NC3=NC(N)=NC(N)=C3N=C2C4=CC=CC(O)=C4)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol], as a form of anti-inflammatory therapy for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). To determine pharmacokinetic profiles, aerosolized formulations of the drug were delivered to mice by a nose-only inhalation route, yielding high pulmonary TG100-115 levels with minimal systemic exposure. Safety assessments were favorable, with no clinical or histological changes noted after 21 days of daily dosing. In a murine asthma model, aerosolized TG100-115 markedly reduced the pulmonary eosinophilia and the concomitant interleukin-13 and mucin accumulation characteristic of this disease. As a functional benefit, interventional dosing schedules of this inhibitor also reduced airway hyper-responsiveness. To model the pulmonary neutrophilia characteristic of COPD, mice were exposed to either intranasal lipopolysaccharide or inhaled smoke. Aerosolized TG100-115 again inhibited these inflammatory patterns, most notably in the smoke model, where interventional therapy overcame the steroid-resistant nature of the pulmonary inflammation. In conclusion, aerosolized TG100-115 displays pharmacokinetic, safety, and biological activity profiles favorable for further development as a therapy for both asthma and COPD. Furthermore, these studies support the hypothesis that PI3K delta and gamma are suitable molecular targets for these diseases. (see: J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. Epub 2008 Dec 4. http://www.ncbi.nlm.nih.gov/pubmed/19056934) Current developer:

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 346.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Xu H, Russell SN, Steiner K, O'Neill E, Jones KI. Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature. Cancer Immunol Immunother. 2024 Aug 6;73(10):204. doi: 10.1007/s00262-024-03779-2. PMID: 39105848; PMCID: PMC11303654. 2: Xu WB, Kotheeranurak V, Zhang HL, Feng JY, Liu JW, Chen CM, Lin GX, Rui G. Identification of the circRNA-miRNA-mRNA regulatory network in osteoarthritis using bioinformatics analysis. Front Genet. 2022 Sep 16;13:994163. doi: 10.3389/fgene.2022.994163. PMID: 36186471; PMCID: PMC9523487. 3: Choi NR, Choi WG, Kwon MJ, Woo JH, Kim BJ. [6]-Gingerol induces Caspase- Dependent Apoptosis in Bladder Cancer cells via MAPK and ROS Signaling. Int J Med Sci. 2022 Jun 21;19(7):1093-1102. doi: 10.7150/ijms.73077. PMID: 35919815; PMCID: PMC9339411. 4: Nadolni W, Immler R, Hoelting K, Fraticelli M, Ripphahn M, Rothmiller S, Matsushita M, Boekhoff I, Gudermann T, Sperandio M, Zierler S. TRPM7 Kinase Is Essential for Neutrophil Recruitment and Function via Regulation of Akt/mTOR Signaling. Front Immunol. 2021 Feb 15;11:606893. doi: 10.3389/fimmu.2020.606893. PMID: 33658993; PMCID: PMC7917126. 5: Song C, Choi S, Oh KB, Sim T. Suppression of TRPM7 enhances TRAIL-induced apoptosis in triple-negative breast cancer cells. J Cell Physiol. 2020 Dec;235(12):10037-10050. doi: 10.1002/jcp.29820. Epub 2020 May 29. PMID: 32468675. 6: Li G, Zhao L. Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment. Drug Deliv. 2019 Dec;26(1):756-764. doi: 10.1080/10717544.2019.1642418. PMID: 31357893; PMCID: PMC6711177. 7: Song C, Bae Y, Jun J, Lee H, Kim ND, Lee KB, Hur W, Park JY, Sim T. Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion. Biochim Biophys Acta Gen Subj. 2017 Apr;1861(4):947-957. doi: 10.1016/j.bbagen.2017.01.034. Epub 2017 Feb 1. PMID: 28161478. 8: Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, Schmid MC, Sun P, Mose E, Bouvet M, Lowy AM, Valasek MA, Sasik R, Novelli F, Hirsch E, Varner JA. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. Cancer Discov. 2016 Aug;6(8):870-85. doi: 10.1158/2159-8290.CD-15-1346. Epub 2016 May 13. PMID: 27179037; PMCID: PMC5091937. 9: Setti A, Kumar MJ, Babu KR, Rasagna A, Prasanna MG, Devi TA, Pawar SC. Potency and pharmacokinetics of broad spectrum and isoform-specific p110γ and δ inhibitors in cancers. J Recept Signal Transduct Res. 2016;36(1):26-36. doi: 10.3109/10799893.2014.1003658. Epub 2015 Oct 13. PMID: 26791581. 10: Liu Y, Xiong L, Chang Y, Tang J, Ang W, Yang T, Pi W, Yang X, Ye W, Luo Y, Wang Z. Phosphoinositide 3-kinase δ/γ inhibition does not prevent concanavalin A-induced hepatitis. Mol Med Rep. 2013 Nov;8(5):1305-10. doi: 10.3892/mmr.2013.1649. Epub 2013 Aug 22. PMID: 23969545. 11: Huet O, Laemmel E, Fu Y, Dupic L, Aprico A, Andrews KL, Moore SL, Harrois A, Meikle PL, Vicaut E, Chin-Dusting JP, Duranteau J. Interleukin 10 antioxidant effect decreases leukocytes/endothelial interaction induced by tumor necrosis factor α. Shock. 2013 Jan;39(1):83-8. doi: 10.1097/SHK.0b013e318278ae36. PMID: 23247124. 12: Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, Dneprovskaia E, Noronha G, Soll R, Wrasidlo W, Acevedo LM, Cheresh DA. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. doi: 10.1124/jpet.108.144311. Epub 2008 Dec 4. PMID: 19056934. 13: Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Hood J, Soll R. Isoform- selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans. 2007 Apr;35(Pt 2):204-6. doi: 10.1042/BST0350204. PMID: 17371238. 14: Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S, Hood J, Demaria A, Soll R, Cheresh D. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71. doi: 10.1073/pnas.0606956103. Epub 2006 Dec 15. PMID: 17172449; PMCID: PMC1702529.